Category ICU

SeaStar Medical Holding Corp

SeaStar Medical ( $ICU )the clinical case is stronger, but the balance sheet still has not caught up . Updated mach 30 with Addendum

SeaStar Medical has spent the last month moving out of the zone where it could be dismissed as a tiny, story-heavy healthcare name with a nice scientific pitch and not much underneath it. The pediatric commercial story is now more tangible, the post-approval burden around SAVE has eased, and the adult pivotal trial has crossed the halfway mark. But that progress has not erased the core financial problem. This is a company with a more credible operating narrative than it had a few months ago, yet still one that openly says it does not have enough capital to fund the next twelve months of planned operations. That tension is the whole ICU story right now.

SeaStar Medical ( $ICU ) before FY2025 earnings

SeaStar Medical goes into its March 25, 2026 earnings date with a story that is more credible medically than it was a few months ago, but not yet more comfortable financially. That distinction matters. In ultra-small medtech and biotech names, better clinical framing can improve perception, but it does not automatically repair a pressured capital structure. SeaStar’s recent updates created a more solid pediatric narrative around QUELIMMUNE, yet the company still faces the far more difficult question of whether that narrative can become durable adoption, durable funding and a less fragile 2026 outlook.

SeaStar Medical Holding Corp ( $ICU )

SeaStar Medical announced completion of the FDA-mandated enrollment requirement (50 patients) for the SAVE Surveillance Registry evaluating QUELIMMUNE safety in pediatric AKI with sepsis requiring continuous kidney replacement therapy (CKRT).

ICU SeaStar Medical Holding Corp

SeaStar Medical is not a typical “pre-clinical biotech on a slide deck”. The company has already crossed the line into real-world use: QUELIMMUNE (the pediatric implementation of the SCD) is approved by the US Food and Drug Administration via HDE and has been adopted by a growing group of leading US children’s hospitals. Early registry data suggest improved survival and kidney recovery in some of the sickest patients in the ICU, with no device-related safety signals reported so far